Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""sorafenib"" wg kryterium: Temat


Tytuł:
Mechanistic Insights about Sorafenib-, Valproic Acid- and Metformin-Induced Cell Death in Hepatocellular Carcinoma.
Autorzy:
Franco-Juárez EX; Departamento de Biología Molecular, Centro de Investigación Biomédica del Noreste, Instituto Mexicano del Seguro Social, Monterrey 64720, Nuevo Leon, Mexico.; Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza 66451, Nuevo Leon, Mexico.
González-Villasana V; Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza 66451, Nuevo Leon, Mexico.
Camacho-Moll ME; Departamento de Biología Molecular, Centro de Investigación Biomédica del Noreste, Instituto Mexicano del Seguro Social, Monterrey 64720, Nuevo Leon, Mexico.
Rendón-Garlant L; Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza 66451, Nuevo Leon, Mexico.
Ramírez-Flores PN; Departamento de Biología Molecular, Centro de Investigación Biomédica del Noreste, Instituto Mexicano del Seguro Social, Monterrey 64720, Nuevo Leon, Mexico.; Tecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey 64710, Nuevo Leon, Mexico.
Silva-Ramírez B; Departamento de Inmunogenética, Centro de Investigación Biomédica del Noreste, Instituto Mexicano del Seguro Social, Monterrey 64720, Nuevo Leon, Mexico.
Peñuelas-Urquides K; Departamento de Biología Molecular, Centro de Investigación Biomédica del Noreste, Instituto Mexicano del Seguro Social, Monterrey 64720, Nuevo Leon, Mexico.
Cabello-Ruiz ED; Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza 66451, Nuevo Leon, Mexico.
Castorena-Torres F; Tecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey 64710, Nuevo Leon, Mexico.
Bermúdez de León M; Departamento de Biología Molecular, Centro de Investigación Biomédica del Noreste, Instituto Mexicano del Seguro Social, Monterrey 64720, Nuevo Leon, Mexico.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 01; Vol. 25 (3). Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Carcinoma, Hepatocellular*/metabolism
Liver Neoplasms*/metabolism
Metformin*/pharmacology
Metformin*/therapeutic use
Humans ; Sorafenib/pharmacology ; Sorafenib/therapeutic use ; Valproic Acid/pharmacology ; Valproic Acid/therapeutic use ; Bevacizumab ; Cell Death
Czasopismo naukowe
Tytuł:
Vinorelbine Improves the Efficacy of Sorafenib against Hepatocellular Carcinoma: A Promising Therapeutic Approach.
Autorzy:
Ng WH; Laboratory of Molecular Endocrinology, National Cancer Centre Singapore, Singapore 168583, Singapore.
Soo KC; Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore 168583, Singapore.
Huynh H; Laboratory of Molecular Endocrinology, National Cancer Centre Singapore, Singapore 168583, Singapore.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 26; Vol. 25 (3). Date of Electronic Publication: 2024 Jan 26.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/metabolism
Liver Neoplasms*/metabolism
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Humans ; Animals ; Mice ; Sorafenib/pharmacology ; Sorafenib/therapeutic use ; Vinorelbine/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Apoptosis ; Cell Line, Tumor ; Cell Proliferation ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł:
MRI radiomics to monitor therapeutic outcome of sorafenib plus IHA transcatheter NK cell combination therapy in hepatocellular carcinoma.
Autorzy:
Yu G; Department of Biomedical Engineering, University of California Irvine, Irvine, CA, USA.
Zhang Z; Department of Radiological Sciences, School of Medicine, University of California Irvine, 839 Health Sciences Rd., Irvine, CA, 92617, USA.
Eresen A; Department of Radiological Sciences, School of Medicine, University of California Irvine, 839 Health Sciences Rd., Irvine, CA, 92617, USA. .
Hou Q; Department of Radiological Sciences, School of Medicine, University of California Irvine, 839 Health Sciences Rd., Irvine, CA, 92617, USA.
Garcia EE; Department of Chemistry, Physical Science, University of California Irvine, Irvine, CA, USA.
Yu Z; Information School, University of Washington, Seattle, WA, USA.
Abi-Jaoudeh N; Department of Radiological Sciences, School of Medicine, University of California Irvine, 839 Health Sciences Rd., Irvine, CA, 92617, USA.; Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA, USA.
Yaghmai V; Department of Radiological Sciences, School of Medicine, University of California Irvine, 839 Health Sciences Rd., Irvine, CA, 92617, USA.; Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA, USA.
Zhang Z; Department of Biomedical Engineering, University of California Irvine, Irvine, CA, USA. .; Department of Radiological Sciences, School of Medicine, University of California Irvine, 839 Health Sciences Rd., Irvine, CA, 92617, USA. .; Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA, USA. .; Department of Pathology and Laboratory Medicine, University of California Irvine, Irvine, CA, USA. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2024 Jan 19; Vol. 22 (1), pp. 76. Date of Electronic Publication: 2024 Jan 19.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/diagnostic imaging
Carcinoma, Hepatocellular*/drug therapy
Liver Neoplasms*/diagnostic imaging
Liver Neoplasms*/drug therapy
Rats ; Animals ; Sorafenib/pharmacology ; Sorafenib/therapeutic use ; Radiomics ; Rats, Sprague-Dawley ; Treatment Outcome ; Biomarkers, Tumor ; Magnetic Resonance Imaging/methods ; Killer Cells, Natural ; Retrospective Studies ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Inhibition of growth of hepatocellular carcinoma by co-delivery of anti-PD-1 antibody and sorafenib using biomimetic nano-platelets.
Autorzy:
Da X; Center of Gallbladder Disease, Shanghai East Hospital, Institute of Gallstone Disease, School of Medicine, Tongji University, 200092, Shanghai, China.
Cao B; School and Hospital of Stomatology, Shanghai Engineering Research Center of Tooth Restoration and Regeneration, Tongji University, 200072, Shanghai, China.
Mo J; Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, 710061, Xi'an, Shaanxi, China.
Xiang Y; Center of Gallbladder Disease, Shanghai East Hospital, Institute of Gallstone Disease, School of Medicine, Tongji University, 200092, Shanghai, China.
Hu H; Center of Gallbladder Disease, Shanghai East Hospital, Institute of Gallstone Disease, School of Medicine, Tongji University, 200092, Shanghai, China.
Qiu C; Center of Gallbladder Disease, Shanghai East Hospital, Institute of Gallstone Disease, School of Medicine, Tongji University, 200092, Shanghai, China.
Zhang C; Center of Gallbladder Disease, Shanghai East Hospital, Institute of Gallstone Disease, School of Medicine, Tongji University, 200092, Shanghai, China.
Lv B; Center of Gallbladder Disease, Shanghai East Hospital, Institute of Gallstone Disease, School of Medicine, Tongji University, 200092, Shanghai, China.
Zhang H; Center of Gallbladder Disease, Shanghai East Hospital, Institute of Gallstone Disease, School of Medicine, Tongji University, 200092, Shanghai, China.
He C; Center of Gallbladder Disease, Shanghai East Hospital, Institute of Gallstone Disease, School of Medicine, Tongji University, 200092, Shanghai, China.
Yang Y; Center of Gallbladder Disease, Shanghai East Hospital, Institute of Gallstone Disease, School of Medicine, Tongji University, 200092, Shanghai, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Feb 26; Vol. 24 (1), pp. 273. Date of Electronic Publication: 2024 Feb 26.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/drug therapy
Liver Neoplasms*/pathology
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Nanoparticles*
Animals ; Mice ; Sorafenib/therapeutic use ; Biomimetics ; Cell Line, Tumor ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma.
Autorzy:
Giannitrapani L; Institute for Biomedical Research and Innovation, National Research Council (CNR), 90146 Palermo, Italy.; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, Italy.
Di Gaudio F; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, Italy.
Cervello M; Institute for Biomedical Research and Innovation, National Research Council (CNR), 90146 Palermo, Italy.
Scionti F; Department of Experimental and Clinical Medicine, Magna Graecia University, 88100 Catanzaro, Italy.
Ciliberto D; Medical and Translational Oncology Unit, A.O.U. R. Dulbecco, 88100 Catanzaro, Italy.
Staropoli N; Department of Experimental and Clinical Medicine, Magna Graecia University, 88100 Catanzaro, Italy.; Medical and Translational Oncology Unit, A.O.U. R. Dulbecco, 88100 Catanzaro, Italy.
Agapito G; Department of Legal, Economic and Social Sciences, Magna Graecia University, 88100 Catanzaro, Italy.
Cannataro M; Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy.
Tassone P; Department of Experimental and Clinical Medicine, Magna Graecia University, 88100 Catanzaro, Italy.; Medical and Translational Oncology Unit, A.O.U. R. Dulbecco, 88100 Catanzaro, Italy.; College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.
Tagliaferri P; Department of Experimental and Clinical Medicine, Magna Graecia University, 88100 Catanzaro, Italy.; Medical and Translational Oncology Unit, A.O.U. R. Dulbecco, 88100 Catanzaro, Italy.
Seidita A; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, Italy.; Villa Sofia-Cervello Hospital, C.O.U. Medical Oncology, 90146 Palermo, Italy.
Soresi M; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, Italy.
Affronti M; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, Italy.
Bertino G; Hepatology Unit, A.O.U. Policlinico-San Marco, Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Russello M; Liver Unit of ARNAS Garibaldi-Nesima, 95100 Catania, Italy.
Ciriminna R; Institute of Nanostructured Materials, National Research Council (CNR), 90146 Palermo, Italy.
Lino C; Institute of Nanostructured Materials, National Research Council (CNR), 90146 Palermo, Italy.
Spinnato F; Villa Sofia-Cervello Hospital, C.O.U. Medical Oncology, 90146 Palermo, Italy.
Verderame F; Villa Sofia-Cervello Hospital, C.O.U. Medical Oncology, 90146 Palermo, Italy.
Augello G; Institute for Biomedical Research and Innovation, National Research Council (CNR), 90146 Palermo, Italy.
Arbitrio M; Institute for Biomedical Research and Innovation, National Research Council (CNR), 88100 Catanzaro, Italy.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 12; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 12.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/genetics
Carcinoma, Hepatocellular*/metabolism
Antineoplastic Agents*/therapeutic use
Liver Neoplasms*/drug therapy
Liver Neoplasms*/genetics
Liver Neoplasms*/metabolism
Humans ; Sorafenib/pharmacology ; Sorafenib/therapeutic use ; Vascular Endothelial Growth Factor A/metabolism ; Niacinamide/therapeutic use ; Phenylurea Compounds/therapeutic use ; Genetic Markers
Czasopismo naukowe
Tytuł:
Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea.
Autorzy:
Han S; Department of Internal Medicine, Uijeongbu Eulji Medical Center, Eulji University College of Medicine, Uijeongbu, Korea.
Kim DY; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Lim HY; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Yoon JH; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Ryoo BY; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim Y; Health Insurance Review and Assessment, Wonju, Korea.
Kim K; Health Insurance Review and Assessment, Wonju, Korea.
Kim BY; Health Insurance Review and Assessment, Wonju, Korea.
Yi SY; Health Insurance Review and Assessment, Wonju, Korea.
Kim DS; Health Insurance Review and Assessment, Wonju, Korea.
Cho DY; Health Insurance Review and Assessment, Wonju, Korea.
Yu J; Health Insurance Review and Assessment, Wonju, Korea.
Kim S; Health Insurance Review and Assessment, Wonju, Korea.
Park JW; Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea.
Pokaż więcej
Źródło:
Gut and liver [Gut Liver] 2024 Jan 15; Vol. 18 (1), pp. 116-124. Date of Electronic Publication: 2023 Jun 19.
Typ publikacji:
Observational Study; Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/pathology
Antineoplastic Agents*/therapeutic use
Chemoembolization, Therapeutic*
Humans ; Sorafenib/therapeutic use ; Retrospective Studies ; Niacinamide/therapeutic use ; Phenylurea Compounds/therapeutic use ; Phenylurea Compounds/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma.
Autorzy:
Chen Q; College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Sun Q; Guangzhou ZhongWei Public Health Technology Accessment Institute, Guangzhou, China.
Zhang J; College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Li B; College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Feng Q; College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Liu J; College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Mar 04; Vol. 19 (3), pp. e0295090. Date of Electronic Publication: 2024 Mar 04 (Print Publication: 2024).
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Liver Neoplasms*/drug therapy
Antibodies, Monoclonal, Humanized*
Humans ; Sorafenib/therapeutic use ; Cost-Effectiveness Analysis
Czasopismo naukowe
Tytuł:
New Opportunities in the Systemic Treatment of Hepatocellular Carcinoma-Today and Tomorrow.
Autorzy:
Becht R; Department of Clinical Oncology, Chemotherapy and Cancer Immunotherapy, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland.
Kiełbowski K; Department of Clinical Oncology, Chemotherapy and Cancer Immunotherapy, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland.
Wasilewicz MP; Liver Unit, Department of Gastroenterology, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 25; Vol. 25 (3). Date of Electronic Publication: 2024 Jan 25.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/drug therapy
Liver Neoplasms*/pathology
Chemoembolization, Therapeutic*
Humans ; Sorafenib/therapeutic use ; Risk Factors
Czasopismo naukowe
Tytuł:
Recent Progress in Systemic Therapy for Advanced Hepatocellular Carcinoma.
Autorzy:
Sadagopan N; MedStar Georgetown Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA.
He AR; MedStar Georgetown Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 19; Vol. 25 (2). Date of Electronic Publication: 2024 Jan 19.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/drug therapy
Liver Neoplasms*/pathology
Humans ; Sorafenib/therapeutic use ; Immunotherapy
Czasopismo naukowe
Tytuł:
Real-world evidence of sorafenib for the treatment of hepatocellular carcinoma: A single-center study.
Autorzy:
Lopez-Lopez A; Department of Pharmacy, University Hospital Complex of Vigo, Spain.
Gayoso-Rey M; Department of Pharmacy, University Hospital Complex of Vigo, Spain.
Garcia-Beloso N; Department of Pharmacy, University Hospital Complex of Vigo, Spain.
Romero-Ventosa Y; Department of Pharmacy, University Hospital Complex of Vigo; NeumoVigo I+i Research Group, Spain.
Robles-Torres D; Department of Pharmacy, University Hospital Complex of Vigo, Spain.
Martinez-Reglero C; Methodology and Statistics Unit, Galicia Sur Health Research Institute, SERGAS-UVIGO, Spain.
Pineiro-Corrales G; Department of Pharmacy, University Hospital Complex of Vigo, Spain.
Pokaż więcej
Źródło:
Journal of cancer research and therapeutics [J Cancer Res Ther] 2023 Jul-Sep; Vol. 19 (5), pp. 1345-1349.
Typ publikacji:
Journal Article; Observational Study
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/drug therapy
Liver Neoplasms*/pathology
Sorafenib*/adverse effects
Aged ; Female ; Humans ; Male ; Middle Aged ; Antineoplastic Agents/adverse effects ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Cancer-associated fibroblasts induce sorafenib resistance of hepatocellular carcinoma cells through CXCL12/FOLR1.
Autorzy:
Zhao J; Department of Hepatobiliary Surgery, Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, 519000, Guangdong, China. .
Lin E; Department of Hepatobiliary Surgery, Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, 519000, Guangdong, China.
Bai Z; Department of Hepatobiliary Surgery, Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, 519000, Guangdong, China.
Jia Y; Department of Urology Surgery, Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, 519000, Guangdong, China.
Wang B; Department of Hepatobiliary Surgery, Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, 519000, Guangdong, China.
Dai Y; Department of Anesthesiology, Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, 519000, Guangdong, China.
Zhuo W; Department of Hepatobiliary Surgery, Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, 519000, Guangdong, China.
Zeng G; Department of Hepatobiliary Surgery, Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, 519000, Guangdong, China.
Liu X; Department of Hepatobiliary Surgery, Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, 519000, Guangdong, China.
Cai C; Department of Hepatobiliary Surgery, Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, 519000, Guangdong, China.
Li P; Department of Hepatobiliary Surgery, Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, 519000, Guangdong, China. .
Zou B; Department of Hepatobiliary Surgery, Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, 519000, Guangdong, China. .
Li J; Department of Hepatobiliary Surgery, Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, 519000, Guangdong, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Dec 06; Vol. 23 (1), pp. 1198. Date of Electronic Publication: 2023 Dec 06.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/genetics
Carcinoma, Hepatocellular*/metabolism
Liver Neoplasms*/drug therapy
Liver Neoplasms*/genetics
Liver Neoplasms*/metabolism
Cancer-Associated Fibroblasts*/metabolism
Humans ; Sorafenib/pharmacology ; Sorafenib/therapeutic use ; Cell Line, Tumor ; Fibroblasts/metabolism ; Drug Resistance, Neoplasm ; Cell Proliferation ; Folate Receptor 1/metabolism ; Folate Receptor 1/therapeutic use ; Chemokine CXCL12/genetics ; Chemokine CXCL12/metabolism
Czasopismo naukowe
Tytuł:
Efficacy and outcome of molecular targeted therapies in elderly patients with hepatocellular carcinoma: Relative dose intensity associated with overall survival.
Autorzy:
Oura K; Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Morishita A; Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Takuma K; Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Nakahara M; Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Tadokoro T; Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Fujita K; Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Mimura S; Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Tani J; Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Ono M; Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Himoto T; Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Kagawa, Japan.
Masaki T; Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Dec; Vol. 12 (24), pp. 22023-22037. Date of Electronic Publication: 2023 Dec 07.
Typ publikacji:
Observational Study; Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/pathology
Antineoplastic Agents*/adverse effects
Humans ; Aged ; Middle Aged ; Sorafenib/therapeutic use ; Molecular Targeted Therapy/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Adjuvant Sorafenib for Postoperative Patients with Hepatocellular Carcinoma and Macrovascular Invasion.
Autorzy:
Chang CJ; Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung 404327, Taiwan.
Hsu WF; Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung 404327, Taiwan.; Graduate Institute of Biomedical Science, China Medical University, Taichung 404328, Taiwan.; School of Chinese Medicine, China Medical University, Taichung 404328, Taiwan.
Jeng LB; Department of Surgery, China Medical University Hospital, Taichung 404327, Taiwan.
Lai HC; Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung 404327, Taiwan.; School of Chinese Medicine, China Medical University, Taichung 404328, Taiwan.
Hsu SC; Department of Surgery, China Medical University Hospital, Taichung 404327, Taiwan.
Chen TH; Department of Surgery, China Medical University Hospital, Taichung 404327, Taiwan.
Wang HW; Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung 404327, Taiwan.; School of Medicine, China Medical University, Taichung 404328, Taiwan.
Peng CY; Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung 404327, Taiwan.; School of Medicine, China Medical University, Taichung 404328, Taiwan.
Pokaż więcej
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2023 Nov 28; Vol. 30 (12), pp. 10134-10141. Date of Electronic Publication: 2023 Nov 28.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/surgery
Liver Neoplasms*/drug therapy
Liver Neoplasms*/surgery
Antineoplastic Agents*/therapeutic use
Humans ; Sorafenib/therapeutic use ; Combined Modality Therapy
Czasopismo naukowe
Tytuł:
Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma.
Autorzy:
Seo SH; Department of Internal Medicine, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Korea.; Yonsei Liver Center, Severance Hospital, Seoul, Korea.
Cho KJ; Yonsei Liver Center, Severance Hospital, Seoul, Korea.
Park HJ; Yonsei Liver Center, Severance Hospital, Seoul, Korea.
Lee HW; Yonsei Liver Center, Severance Hospital, Seoul, Korea.; Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Korea.
Kim BK; Yonsei Liver Center, Severance Hospital, Seoul, Korea.; Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Korea.
Park JY; Yonsei Liver Center, Severance Hospital, Seoul, Korea.; Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Korea.
Kim DY; Yonsei Liver Center, Severance Hospital, Seoul, Korea.; Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Korea.
Ahn SH; Yonsei Liver Center, Severance Hospital, Seoul, Korea.; Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Korea.
Cheon JH; Department of Internal Medicine, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Korea.; Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Korea.; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Yook JI; Department of Oral Pathology, Yonsei University College of Dentistry, Seoul, Korea.
Kim MD; Department of Radiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Joo DJ; Department of Surgery, Yonsei University of College of Medicine, Seoul, Korea.
Kim SU; Yonsei Liver Center, Severance Hospital, Seoul, Korea. .; Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Korea. .
Pokaż więcej
Źródło:
Cell communication and signaling : CCS [Cell Commun Signal] 2023 Nov 27; Vol. 21 (1), pp. 339. Date of Electronic Publication: 2023 Nov 27.
Typ publikacji:
Video-Audio Media; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Hepatocellular*/genetics
Liver Neoplasms*/metabolism
Humans ; Mice ; Animals ; Sorafenib/pharmacology ; Glycogen Synthase Kinase 3 beta ; Proto-Oncogene Proteins c-akt/metabolism ; Phosphatidylinositol 3-Kinases/metabolism ; beta Catenin/metabolism ; Cell Proliferation ; Cell Line, Tumor
Czasopismo naukowe
Tytuł:
Impact of skeletal muscle volume on patients with BCLC stage-B hepatocellular carcinoma undergoing sorafenib therapy.
Autorzy:
Saeki I; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
Yamasaki T; Department of Oncology and Laboratory, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
Yamauchi Y; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
Kawaoka T; Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Uchikawa S; Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Hiramatsu A; Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Aikata H; Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Kobayashi K; Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.; Translational Research and Development Center, Chiba University Hospital, Chiba, Japan.
Kondo T; Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Ogasawara S; Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.; Translational Research and Development Center, Chiba University Hospital, Chiba, Japan.
Chiba T; Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Kawano R; National Center for Geriatrics and Gerontology, Innovation Center for Translational Research, Aichi, Japan.
Chayama K; Collaborative Research Laboratory of Medical Innovation, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.; Research Center for Hepatology and Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.; RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Kato N; Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Takami T; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 May; Vol. 12 (9), pp. 10625-10635. Date of Electronic Publication: 2023 Mar 23.
Typ publikacji:
Journal Article
MeSH Terms:
Muscle, Skeletal*/pathology
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/mortality
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/drug therapy
Liver Neoplasms*/mortality
Liver Neoplasms*/pathology
Sorafenib*/therapeutic use
Antineoplastic Agents*/therapeutic use
Humans ; Neoplasm Staging ; Male ; Female ; Middle Aged ; Aged ; Prognosis ; Progression-Free Survival
Czasopismo naukowe
Tytuł:
Aptamer-mediated hollow MnO 2 for targeting the delivery of sorafenib.
Autorzy:
Wang Z; Department of Molecular Imaging, School of Medical Technology, Qiqihar Medical University, Qiqihar, China.
Wu C; Department of Molecular Imaging, School of Medical Technology, Qiqihar Medical University, Qiqihar, China.
Liu J; Department of Molecular Imaging, School of Medical Technology, Qiqihar Medical University, Qiqihar, China.
Hu S; Department of Molecular Imaging, School of Medical Technology, Qiqihar Medical University, Qiqihar, China.
Yu J; Department of Molecular Imaging, School of Medical Technology, Qiqihar Medical University, Qiqihar, China.
Yin Q; Department of Molecular Imaging, School of Medical Technology, Qiqihar Medical University, Qiqihar, China.
Tian H; Department of Molecular Imaging, School of Medical Technology, Qiqihar Medical University, Qiqihar, China.
Ding Z; Department of Molecular Imaging, School of Medical Technology, Qiqihar Medical University, Qiqihar, China.
Qi G; Department of Molecular Imaging, School of Medical Technology, Qiqihar Medical University, Qiqihar, China.
Wang L; Department of Personnel, the Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, China.
Hao L; Department of Molecular Imaging, School of Medical Technology, Qiqihar Medical University, Qiqihar, China.
Pokaż więcej
Źródło:
Drug delivery [Drug Deliv] 2023 Dec; Vol. 30 (1), pp. 28-39.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Liver Neoplasms*/drug therapy
Humans ; Animals ; Mice ; Sorafenib ; Manganese Compounds ; Oxides ; Oligonucleotides ; Tumor Microenvironment ; Glypicans
Czasopismo naukowe
Tytuł:
Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study.
Autorzy:
Lu H; Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue #1277, Wuhan, 430022, China.; Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China.
Liang B; Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue #1277, Wuhan, 430022, China.; Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China.
Xia X; Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue #1277, Wuhan, 430022, China.; Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China.
Zheng C; Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue #1277, Wuhan, 430022, China. .; Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Oct 25; Vol. 23 (1), pp. 1033. Date of Electronic Publication: 2023 Oct 25.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/pathology
Antineoplastic Agents*/therapeutic use
Liver Neoplasms*/drug therapy
Liver Neoplasms*/pathology
Chemoembolization, Therapeutic*/adverse effects
Humans ; Sorafenib/adverse effects ; Retrospective Studies ; Niacinamide/adverse effects ; Phenylurea Compounds/adverse effects
Czasopismo naukowe
Tytuł:
DLAT is a promising prognostic marker and therapeutic target for hepatocellular carcinoma: a comprehensive study based on public databases.
Autorzy:
Zhang P; Nantong Institute of Liver Disease, Department of Hepatobiliary Surgery, Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.
Zhao JH; Medical School of Nantong University, Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.
Yuan LX; Nantong Institute of Liver Disease, Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.
Ju LL; Nantong Institute of Liver Disease, Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.
Wang HX; Nantong Institute of Liver Disease, Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.
Wang F; Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.
Chen L; Nantong Institute of Liver Disease, Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China. .
Cai WH; Department of Hepatobiliary Surgery, Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Oct 12; Vol. 13 (1), pp. 17295. Date of Electronic Publication: 2023 Oct 12.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/genetics
Dihydrolipoyllysine-Residue Acetyltransferase*
Liver Neoplasms*/drug therapy
Liver Neoplasms*/genetics
Humans ; Prognosis ; Sorafenib/therapeutic use
Czasopismo naukowe
Tytuł:
Unusual Presentation of an Uncommon Malignancy: A 74-Year-Old Woman with Aggressive Fibromatosis of the Large Intestine Presenting as a Liver Mass and the Therapeutic Management.
Autorzy:
Vallilas C; Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Papadakos SP; Department of Gastroenterology, General Hospital of Athens 'Laiko' Medical School of National and Kapodistrian University of Athens, Athens, Greece.
Androutsakos T; Department of Pathophysiology, 'Laikon' General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Pergaris A; First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Sarantis P; Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Apostolidi EA; Department of Pathophysiology, 'Laikon' General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Griniatsos J; First Department of Surgery, Laiko Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Karamouzis MV; Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Sougioultzis S; Department of Pathophysiology, 'Laikon' General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Pokaż więcej
Źródło:
The American journal of case reports [Am J Case Rep] 2023 Oct 09; Vol. 24, pp. e939862. Date of Electronic Publication: 2023 Oct 09.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Fibromatosis, Aggressive*/diagnostic imaging
Fibromatosis, Aggressive*/surgery
Liver Neoplasms*/diagnostic imaging
Female ; Humans ; Aged ; Sorafenib ; Tamoxifen
Czasopismo naukowe
Tytuł:
Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis.
Autorzy:
Li Y; Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Yang W; Department of Emergency, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Zheng Y; Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Dai W; Department of Gastroenterology, Shidong Hospital, Shanghai, 200433, China.
Ji J; Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Wu L; Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Cheng Z; Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Zhang J; Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Li J; Department of Gastroenterology, Shidong Hospital, Shanghai, 200433, China.
Xu X; Department of Gastroenterology, Shidong Hospital, Shanghai, 200433, China.
Wu J; Department of Gastroenterology, Putuo People's Hospital, Tongji University, Shanghai, 200060, China.
Yang M; Department of Oncology Radiotherapy, The First Affiliated Hospital of Anhui Medical University, Hefei, 230031, China. yangmw_.
Feng J; Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China. .
Guo C; Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China. .
Pokaż więcej
Źródło:
Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2023 Jan 06; Vol. 42 (1), pp. 6. Date of Electronic Publication: 2023 Jan 06.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/genetics
Carcinoma, Hepatocellular*/metabolism
Ferroptosis*
Liver Neoplasms*/drug therapy
Liver Neoplasms*/genetics
Liver Neoplasms*/metabolism
Sorafenib*/pharmacology
Sorafenib*/therapeutic use
Humans ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; Fatty Acid Synthases/metabolism ; Orlistat/pharmacology ; Orlistat/therapeutic use
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies